Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado.
Research context
Cleveland BioLabs Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Cleveland BioLabs, Inc is currently in a long term uptrend where the price is trading 5.3% above its 200 day moving average.
From a valuation standpoint, the stock is 78.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 294.7.
Cleveland BioLabs, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has increased by 1.8% to $-695K since the same quarter in the previous year.
Finally, its free cash flow fell by 115.4% to $-788K since the same quarter in the previous year.
Based on the above factors, Cleveland BioLabs, Inc gets an overall score of 3/5.